Featured Videos & Audios
Here you will find some of our featured presentations and interviews.
Cell & Gene
Therapy Explained
An AGT Video Series
Companies like AGT are doing groundbreaking research and developing innovative ways to combat diseases. This series of videos will take an inside look at how gene and cell therapy technologies work, what it is like to be part of an innovative gene and cell therapy company, and what these technologies mean for the future of medicine.
Virtual Press Conference: FDA Clears AGT to Begin Phase 1 Clinical Trial of HIV Cure Program
AGT was excited to announce its clearance by the FDA to begin a Phase I Trial for an HIV cure. The company hosted a virtual press conference to answer questions from reporters. Here is a video recording of the press conference.
Cell and Gene Therapy: Discovering The Clinical & Commercial Potential - Jeff Galvin Webinar
Jeff Galvin Presents "Discovering The Clinical & Commercial Potential of Cell and Gene Therapy" at the Databridge (DBMR) Conference Series on Cell and Gene Therapy on July 31st, 2020.
The New Economics and Efficiencies of Gene Therapy - Jeff Galvin Presents at Biopharma Connections
In this BioPharma Connections webinar, CEO of AGT, Jeffrey Galvin explains how biotechnology is moving forward at an incredible rate. Gene and cell therapy is moving closer to an HIV Cure, and has been approved for a human trial since the recording of this webinar.
BioNeex Interview with CEO of American Gene Technologies, Jeff Galvin
BioNeex, a Biopharmaceutical R&D exchange platform for compounds licensing and co-development partnerships, created an interview series of innovative CEOs and executives to provide value to its customers and the biotechnology industry. Founder Dr. Smbat Rafayelyan interviewed AGT CEO Jeff Galvin as part of its series.
HIV IMMUNITY
Dr. Hardy Shares the Possibilities of Gene Therapy
Contrary to antiretroviral drugs, gene therapy could be used to give the human body immunity to HIV. Dr. David Hardy, a member of American Gene Technologies (AGT)’s HIV Scientific Advisory Board, tells his story of his lifelong commitment to mitigate the effects of the HIV virus.
Gene Therapy Technology – Reprogramming The Human Computer
Jeff Galvin, CEO of American Gene Technologies (AGT), explains his ascent into the biotechnology drug development field after working closely with computers in Silicon Valley for a large part of his life.
CAN HIV BE CURED?
These Two HIV+ Clinical Trial Participants Believe It Can.
Watch this video interview of two HIV+ men that decided to participate in clinical trials with varying success. Despite their different experiences with human trials and different outcomes following treatment, Matt C. and Matt S. are both still advocates for clinical trial participation and encourage others to support HIV cure research aimed at finding an HIV cure.
CEO Jeff Galvin Speaks on Biotech IPO Trends and Outlook Panel At BIO CEO & Investor Conference 2020
AGT's Jeff Galvin speaks on panel at the BIO CEO & Investor Conference on Feb 10-11 in NYC. The panel discussed IPO trends and outlook for 2020. The 2020 BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. Experience the best of biotech with two days of productive partnering meetings with institutional and early-stage investors, industry analysts, and senior biotechnology executives, in one location. About the conference.
CEO Jeff Galvin Kirwan Commission Testimony To Maryland Legislator
Delegate Jared Solomon invited CEO Jeff Galvin to testify to state legislators in Annapolis, Maryland on February 17, 2020. Galvin served as the linkage between public education and the workforce talent pool needed for a thriving Maryland biotech companies, like American Gene Technologies. Listen to his testimony that was recorded live.
Chief Science Officer Dr. C. David Pauza Presents at Cell & Gene Meeting On The Mesa 2019
The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. Dr. Pauza was a featured presenter at the conference (press release). In his presentation, he announced details about AGT's pending submission of an IND for a cell & gene therapy for HIV.
EXECUTIVE LEADERSHIP RADIO SHOW ON WFED 1500AM INTERVIEWED CEO JEFF GALVIN
On July 7, 2019, Executive Leadership Radio hosts Herb Cohen and Jeffrey E. Mack interviewed CEO Jeff Galvin. This interview gets to the heart of Galvin's life story, his parents, his experience growing up in Massachusetts, and what led him to the Washington, D.C. area to found American Gene Technologies.
Show is aired on: WFED Federal News Radio 1500 AM
Gene Technologies are Making Strides to Cure Terminal Illnesses
Published By: What's Working In Washington | Federal News Network
Even if you work in the D.C. region, you may not be privy to a world-changing industrial revolution happening right now, in places around the world. To talk about that is Jeff Galvin, CEO and founder of American Gene Technologies. Galvin is an expert on how innovations in gene research can begin to change the world.
Washington D.C.'s Wonk FM & iHeart Radio Interview Jeff Galvin on Show: Emerging Technology
On May 17, 2019, host Stacy Lyn interviews Jeff Galvin on how AGT is using HIV to cure cancer. The interview aired as part of Wonk FM's focus on Emerging Technology.
Dr. David Pauza, Chief Science Officer
Explains Why He's Determined To Cure HIV. Watch his story.
C. David Pauza, Ph.D. is Chief Science Officer for American Gene Technologies and Professor of Medicine at the University of Maryland Medical School in Baltimore. Prior to joining AGT, Dr. Pauza was Associate Director for the university’s prestigious Institute of Human Virology and Co-Leader of the Greenebaum Cancer Center Program in Viral Oncology. He is an internationally recognized expert in human virology and viral diseases including HIV, arenaviruses, poxviruses and herpesviruses. He has published more than 150 scientific papers and holds 7 US patents.
BIO2019 PRESENTATION: JEFF GALVIN SPEAKS TO AUDIENCE ABOUT AGT'S SCIENCE, EXPERTS, AND PLANS FOR FDA IND SUBMISSION
On June 4th between 1:45 –2:00 pm, CEO Jeff Galvin spoke to audiences attending BIO2019 about AGT's scientific discoveries, its team of experts, and its plan to move its pre-clinical therapies into the clinic. BIO (Biotechnology Innovation Organization) is the largest trade organization in the world that represents the biotechnology industry.
Built For Bio: Jeff Galvin, CEO & Founder of American Gene Technologies
Montgomery County Economic Development Corporation (MCEDC) discovers how CEO Jeff Galvin is using the availability of raw talent and novel technology unique to Montgomery County, Maryland to help cure HIV and cancers with gene and cell therapy research.
Jeff Galvin Presents at ARM's 7th Annual Cell & Gene Therapy Investor Day
CEO Jeff Galvin presents at Alliance for Regenerative Medicine (ARM)’s 7th Annual Cell & Gene Therapy Investor Day. The event provides institutional, strategic and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools.
Dr. Ely Benaim, Scientific Advisor
Explains Why He Believes In AGT's Science. Dr. Ely Benaim has spent 25 years in healthcare, has 15 years of clinical experience in academia, government, pharma, and has worked at St. Jude Children's Research Hospital, Amgen, Sangamo Therapeutics, Takeda, and more. Learn why he believes in AGT as a scientific advisor for its HIV cure program. Watch his story.
State Recognizes AGT as a Maryland Success Story
The State of Maryland recognizes American Gene Technologies as a Maryland Success Story because of the accelerated progress it is making to reshape how deadly diseases are treated through gene and cell therapy cures. CEO Jeff Galvin talks with Maryland about the company's success in the State.
IS THE CURE FOR CANCER RIGHT AROUND THE CORNER?...
HOW CREATIVITY CURES | JEFF GALVIN,
AGT CEO | TEDxGEORGETOWN
CEO Jeff Galvin tours nationally to evangelize AGT’s mission and raise awareness of AGT’s commitment to pursuing solutions for patients suffering from intractable diseases. Watch his latest TEDx talk to learn about the tremendous potential and progress in gene and cell therapy, and what AGT and other biotechs are doing to treat (and even cure!) serious human health conditions such as cancers and HIV.
AGT VIRAL VECTOR TECHNOLOGY AND INDUSTRY OVERVIEW
Advances in gene technologies and the resulting cures are accelerating exponentially while costs are coming down. If you were in Silicon Valley for the last 35 years, you’d recognize parallels to many previous high-tech “explosions” such as microcomputers, software and the Internet. “Moore’s Law” now applies to drug development and the next big startup could be up in a garage near you! Forget zeroes and ones… A-C-G-T is the new growth area of programming and real-world solutions. Viva la revolution!
JEFF GALVIN, AGT CEO, INTERVIEWED BY GUY FLYNN (DLA/PIPER PARTNER) FOR CITYBIZLIST ON AGT HISTORY, TECHNOLOGY AND PROGRESS
A national media company, CityBizList, published an interview with Jeff Galvin in a three part “CEO Interview” series. Feedback from viewers indicated that it gives an easy-to-understand background and explanation of AGT’s work and mission. If you are interested, you can view the three part interview below.
Jeff Galvin meets Dr. Roscoe Brady:
AGT is born
How gene and cell therapy will change the world and disrupt the pharmaceutical market
How AGT is using HIV to cure HIV! The future of gene technologies Part 3
AGT’S CSO, C. DAVID PAUZA, PHD, GIVES KEYNOTE SPEECH AT THE CELL AND GENE MEETING ON THE MESA
C. David Pauza, PhD, Chief Science Officer at American Gene Technologies (AGT), presented twice at The Cell and Gene Meeting on the Mesa conference hosted by the Alliance for Regenerative Medicine (ARM). His company presentation focused on the status and progress of AGT’s development of an HIV cure (human trials currently forecast by AGT to begin in 2018). Dr. Pauza also gave the keynote presentation elaborating on how the industry is benefiting from an understanding of and continued research into the human immune system that is opening opportunities to address a wide variety of diseases utilizing gene and cell therapies.
AGT CEO AND FOUNDER, JEFFREY A. GALVIN, GIVES PRESENTATION AT NOBLECON13
Watch CEO Jeff Galvin’s presentation at NobleCon to hear the pitch. His vision for AGT and biotech is infectious. “There is a revolution in drug development that very few people realize…we can attack diseases at their root cause. Gene technology is extremely powerful and it works”.
